iSpecimen (ISPC)

Its offering includes access to human biofluids, solid tissue, stem cells, immune cells, and other sample types used in areas such as oncology, immunology, infectious disease, genomics, and biomarker research. Researchers rely on these materials to validate assays, study disease mechanisms, support clinical and translational research, and develop new therapeutic or diagnostic products. iSpecimen’s role is to help match scientific requirements with available specimens while managing logistics, compliance, and data-related needs.

The company generates revenue by sourcing and delivering specimens to life science customers, including biotechnology companies, pharmaceutical companies, diagnostic developers, academic institutions, and contract research organisations. Its operations span the Americas, Europe, the Middle East, Africa, and Asia Pacific, although the Americas represent its largest geographic contributor. iSpecimen reports its business as a single biospecimens segment.

For investors, ISPC is a small-cap healthcare services and technology stock tied to the growth of precision medicine, biomedical research, and outsourced research infrastructure. Its prospects depend on expanding supplier relationships, increasing customer demand, maintaining high standards for specimen quality and ethical sourcing, and competing effectively in a specialised market. The company’s distinctive position lies in combining a digital procurement platform with a global network of biospecimen providers.